华润双鹤药业股份有限公司 第十届监事会第十一次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 整性承担法律责任。 一、监事会会议召开情况 公司第十届监事会第十一次会议的召开符合《公司法》和公司《章 程》的有关规定。本次会议通知和材料于 2025 年 10 月 20 日以邮件 方式向全体监事发出，会议于 2025 年 10 月 23 日以现场及通讯方式 召开。出席会议的监事应到 5 名，亲自出席会议的监事 5 名。会议由 监事会主席刘建国先生主持。公司董事会秘书刘驹先生列席会议。 二、监事会会议审议情况 第十届监事会第十一次会议 2025 年 10 月 23 日 证券代码：600062 证券简称：华润双鹤 公告编号：临 2025－091 除限售期解除限售条件成就的议案 5 票同意，0 票反对，0 票弃权。 3、关于回购注销部分激励对象已获授但尚未解除限售的限制性股 票的议案 5 票同意，0 票反对，0 票弃权。 1、关于 2025 年第三季度报告的议案 公司监事会对 2025 年第三季度报告进行了审核，提出如下审核 意见： 2025 ...

第十届董事会第十四次会议 2025 年 10 月 23 日 证券代码：600062 证券简称：华润双鹤 公告编号：临 2025－087 华润双鹤药业股份有限公司 第十届董事会第十四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 整性承担法律责任。 一、董事会会议召开情况 公司第十届董事会第十四次会议的召开符合《公司法》和公司《章 程》的有关规定。本次会议通知和材料于 2025 年 10 月 20 日以邮件方 式向全体董事发出，会议于2025 年10 月23 日以现场及通讯方式召开。 出席会议的董事应到 11 名，亲自出席会议的董事 11 名。会议由董事 长陆文超先生主持。公司监事列席会议。公司董事会秘书刘驹先生列 席会议。 二、董事会会议审议情况 1、关于2025年第三季度报告的议案 《 2025 年 第 三 季 度 报 告 》 详 见 上 海 证 券 交 易 所 网 站 www.sse.com.cn 及《中国证券报》《上海证券报》《证券时报》。 审计与风险管理委员会意见：同意。 2、关于公司2021年限制性股票激励计划预留授予 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 （於香港註冊成立的有限公司） （股份代號：3320） 公 告 華潤雙鶴 截至2025年9月30日止九個月的未經審核財務業績 於2025年10月24日，華潤雙鶴公佈其截至2025年9月30日止九個月的季度報 告。 | | 2025年 | 2024年 | | --- | --- | --- | | | （人民幣） | （人民幣） | | | （未經審核） | （未經審核） | | 營業總收入 | 8,283,222,411.30 | 8,548,241,751.78 | | 淨利潤 | 1,388,212,831.84 | 1,411,764,462.20 | | 現金及現金等價物淨減少額 | （630,388,437.05） | (509,288,867.81) | | 期末現金及現金等價物餘額 | 2,207,726,715.86 | 2,698,854,450.15 | | | 截至2025年 | ...

Financial Performance - The company's revenue for Q3 2025 was CNY 2,541,712,604.50, a decrease of 2.96% compared to the same period last year[6] - The total profit for the period was CNY 398,345,525.38, down 5.81% year-on-year[6] - Net profit attributable to shareholders was CNY 374,043,930.88, an increase of 6.71% compared to the previous year[6] - The company's total revenue for the first three quarters of 2025 was RMB 8.28 billion, down from RMB 8.55 billion in the same period of 2024, representing a decline of about 3.13%[18] - Operating profit for the first three quarters of 2025 was RMB 1.59 billion, slightly up from RMB 1.59 billion in the same period of 2024, indicating stable performance[18] - The total profit for the first three quarters of 2025 is approximately CNY 1.62 billion, slightly up from CNY 1.62 billion in the same period of 2024, reflecting a marginal increase of 0.03%[19] - Net profit for the first three quarters of 2025 is CNY 1.39 billion, down from CNY 1.41 billion in 2024, indicating a decrease of about 2.5%[19] - The company reported a net profit margin of approximately 19.19% for the first three quarters of 2025, consistent with the previous year's performance[18] Earnings and Shareholder Information - Basic earnings per share for the quarter were CNY 0.3600, up 6.82% year-on-year[6] - The basic earnings per share for the first three quarters of 2025 is CNY 1.3077, compared to CNY 1.3596 in 2024, representing a decline of approximately 3.8%[19] - Shareholder equity attributable to the parent company increased by 8.75% to CNY 11,318,550,040.76[7] - The company had a total of 57,726 ordinary shareholders at the end of the reporting period[12] - The company's equity attributable to shareholders increased to RMB 11.32 billion as of September 30, 2025, compared to RMB 10.41 billion at the end of 2024, an increase of about 8.74%[17] Cash Flow and Assets - The net cash flow from operating activities decreased by 21.62% to CNY 1,147,181,437.63 year-to-date[6] - Cash flow from operating activities for the first three quarters of 2025 is CNY 1.15 billion, down from CNY 1.46 billion in 2024, a decrease of about 21.5%[20] - Cash inflow from investment activities in the first three quarters of 2025 is CNY 661.79 million, significantly lower than CNY 1.72 billion in 2024, a decline of approximately 61.5%[21] - Cash flow from financing activities for the first three quarters of 2025 shows a net outflow of CNY 1.26 billion, compared to a net outflow of CNY 3.07 billion in 2024, indicating an improvement in cash flow management[21] - The company's cash and cash equivalents as of September 30, 2025, were RMB 2.22 billion, down from RMB 2.85 billion at the end of 2024, a decrease of about 22.05%[15] - The ending cash and cash equivalents balance as of September 2025 is CNY 2.21 billion, down from CNY 2.70 billion at the end of September 2024, a decrease of about 18.1%[21] Assets and Liabilities - Total assets at the end of the period were CNY 17,013,714,914.48, reflecting a 1.96% increase from the end of the previous year[7] - As of September 30, 2025, total assets amounted to RMB 17.01 billion, an increase from RMB 16.69 billion as of December 31, 2024[16] - Total liabilities decreased to RMB 4.85 billion as of September 30, 2025, compared to RMB 5.57 billion at the end of 2024, reflecting a reduction of approximately 12.96%[17] Research and Development - Research and development expenses for the first three quarters of 2025 were RMB 371 million, a decrease of approximately 21.43% from RMB 473 million in the same period of 2024[18] Inventory and Operating Expenses - The company's inventory as of September 30, 2025, was RMB 1.64 billion, slightly up from RMB 1.59 billion at the end of 2024, reflecting an increase of approximately 6.67%[15] - The company has incurred operating expenses of CNY 8.29 million in the first three quarters of 2025, compared to CNY 6.91 million in 2024, reflecting an increase of about 19.9%[19] Strategic Developments - The company acquired a 53.28% stake in Henan Zhongshuai Pharmaceutical Technology Co., Ltd. for a transaction amount of RMB 348 million, completed on September 28, 2025, and included in the consolidated financial statements from that date[14] - The company has not indicated any new product launches or significant market expansion strategies during this reporting period[22]

华润双鹤公告，第三季度营收为25.42亿元，同比下降2.96%；净利润为3.74亿元，同比增长6.71%。前 三季度营收为82.83亿元，同比下降3.10%；净利润为13.5亿元，同比下降3.40%。 ...

Core Viewpoint - China Resources Double Crane announced its profit distribution plan for the first half of 2025, detailing a cash dividend of 0.10 yuan per share (tax included) for A-shares [2] Summary by Sections - **Dividend Announcement** - The company will distribute a cash dividend of 0.10 yuan per share for the first half of 2025 [2] - The record date for the dividend is set for October 27, 2025 [2] - The ex-dividend date and the date of cash dividend payment are both scheduled for October 28, 2025 [2]

Core Viewpoint - China Resources Double Crane (华润双鹤) announced a cash dividend distribution plan for the first half of 2025, indicating a commitment to returning value to shareholders through cash dividends [1] Group 1: Dividend Distribution Details - The total share capital before the implementation of the plan is 1.039 billion shares [1] - A cash dividend of 0.10 yuan (including tax) will be distributed per share, totaling 104 million yuan (including tax) [1] - The record date for the dividend is set for October 27, 2025, and the payment date is October 28, 2025 [1]

证券代码：600062 证券简称：华润双鹤 公告编号：临 2025-086 华润双鹤药业股份有限公司 2025年半年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.10元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权(息)日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/10/27 | － | 2025/10/28 | 2025/10/28 | 差异化分红送转：否 一、通过分配方案的股东会届次和日期 本次利润分配方案经公司2025 年 9 月 9 日的2025年第二次临时 股东会审议通过。 二、分配方案 1.发放年度：2025年半年度 四、分配实施办法 1. 实施办法 除公司自行发放对象外，其他股东的红利委托中国结算上海分公 司通过其资金清算系统向股权登记日上海证券交易所收市后登记在 册并在上海证券交易所各会员办理了指定交易的股东派发。已办理指 定交易的投资者可于红利发 ...

Core Viewpoint - The company announced that its wholly-owned subsidiary, Beijing Wanhui Shuanghe Pharmaceutical Co., Ltd., has received a drug registration certificate for Alfacalcidol soft capsules from the National Medical Products Administration, which is expected to enhance the company's product line and market competitiveness [1][2]. Drug Registration Certificate Details - The drug is indicated for treating calcium metabolism disorders caused by insufficient endogenous 1,25-dihydroxyvitamin D3, including conditions such as renal osteodystrophy and osteoporosis [1][2]. - The company initiated the drug's generic research and development in August 2022, submitted the marketing authorization application in June 2024, and received approval on October 14, 2025 [2]. Market Situation - Alfacalcidol soft capsules were developed by LEO Pharma A/S and were approved for sale in the Netherlands in 1978 under the brand name "Etalpha," which was also approved in China in May 2023 [2]. - The global sales of Alfacalcidol capsules are projected to reach $182 million in 2024, with "Etalpha" contributing $14.13 million [2]. - In the Chinese market, there are nine approved manufacturers of Alfacalcidol soft capsules, with three having passed the consistency evaluation, including Wanhui Shuanghe [3]. - The total sales in the domestic medical and retail market for Alfacalcidol soft capsules are estimated at 659 million RMB in 2024, with the top three companies holding market shares of 36.53%, 17.65%, and 17.27% respectively [3].

Core Viewpoint - China Resources Double Crane announced that its wholly-owned subsidiary, Beijing Wanhui Double Crane Pharmaceutical Co., Ltd., has received the Drug Registration Certificate for Alfacalcidol Soft Capsules from the National Medical Products Administration [2] Group 1 - The announcement was made on the evening of October 20 [2] - The Drug Registration Certificate is a significant regulatory milestone for the company [2] - Alfacalcidol is a medication used to treat conditions related to calcium metabolism [2]